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Using the Medication Cabinet to Predict Fall Risk in Elderly Adults 
 
 
Abstract 
 
 
 
by  
 
 
Jessica M. Lopez 
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2017 
 
Background: In the United States, 30-60% of older adults fall each year; 10-20% of 
these falls result in injury, hospitalization, or even death.  Better prevention of falls in this 
population may be facilitated by broader identification of risk factors.  The use of statins 
has emerged as a potential risk factor, but the data provide conflicted results.   
Purpose: To examine the relationship between statin use and falls among community-
dwelling older adults.   
Methods: We evaluated the patient registry of a Level 1 trauma center.  All patients aged 
> 50 years who were admitted for falls in 2015 were included (n=615).  Many of these 
patients had been previously admitted for falls and many were later readmitted for falls.  
We analyzed predictors of both prior admission and readmission with linear regressions.  
Independent variables were self-reported balance problems, diagnosis of dementia, and 
the use of statins.   
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Results: On average, patients admitted for falls were 79.9 + 9.3 years old and 28% 
(n=173) were taking statins.  Our collection of predictors explained 14.2% of the variance 
in the number of prior admissions (p<0.001).  In this model, the use of statins 
significantly predicted the number of previous fall-related admissions (95% CI: 0.07–
0.50, p=0.010).  This same model maintained its significance when predicting admissions 
for future falls (p<0.001) and the use of statins continued to predict a greater number of 
readmissions (95% CI: 0.04–0.36, p=0.015).   
Conclusion: More than 25% of all Americans age > 40 years are taking cholesterol-
lowering medication; 93% of those medications are statins.  Although evidence is 
conflicted, these data support the finding that statin therapy increases the risk of falls in 
older adults.  Incorporating exercise training as a prophylactic measure: enhancing lipid 
profiles and decreasing the need for statins while also improving balance, coordination, 
and mobility, may reduce fall-related injuries.  
 
 
 
 
 
7		
	
TABLE OF CONTENTS 
 
LIST OF TABLES………………………………………………………………………...9 
LIST OF FIGURES……………………………………………………………………...10 
CHAPTER 
1. Introduction………………………………………………………………………11 
1.1 Research hypothesis…………………………………………………………12 
1.2 Purpose……………………………………………………………………...13 
1.3 Null Hypothesis…………………………………………………………......13 
1.4 Delimitations………………………………………………………………...13 
1.5 Limitations…………………………………………………………………..13 
2. Review of the Literature…………………………………………………………14 
2.1 Fall Occurrence, Risk Factors, and Consequences………………………….14 
2.2 Statin Overview……………………………………………………………..16 
2.3 Cholesterol Synthesis……………………………………………………….17 
2.4 The Role of Statins in Cholesterol Synthesis……………………………….20 
2.5 Proposed Mechanisms of Statin-Induced Myopathy…………………….....22 
2.6 Statins and Fall-Risk………………………………………………………...25 
3. Methodology……………………………………………………………………..28 
3.1 Data Acquisition and Management…………………………………………28 
3.2 Subjects……………………………………………………………………...28 
3.3 Statistical Analysis…………………………………………………………..29 
4. Draft of Manuscript………………………………………………………………30 
4.1 Title………………………………………………………………………….30 
8		
	
4.2 Abstract……………………………………………………………………...30 
4.3 Introduction………….………………………………………………………31 
4.4 Methods…………………………………………………………………......32 
4.5 Results..……………………………………………………………………...33 
4.6 Discussion…………………………………………………………………...36 
REFERENCES…………………………………………………………………………..39 
APPENDIX A……………………………………………………………………………42 
APPENDIX B……………………………………………………………………………43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9		
	
LIST OF TABLES 
 
 
Table                Page 
1. Proposed Definitions for Statin-Related Myopathy……………………………...22 
2. Demographic Data, Number of Falls, and Diagnoses……………………..……..34 
3. Linear Regression Analysis Predicting Number of Previous Admissions for 
Falls………………………………………………………………………………35 
 
4. Linear Regression Analysis Predicting Number of Return Emergency Room 
Visits……………………………………………………………………………..36 
 
 
 
 
 
 
 
 
 
 
10		
	
LIST OF FIGURES 
 
Figure                 Page 
1. Compartmentation and Simplified Biochemistry of Cholesterol Synthesis……..19 
 
 
 
 
 
 
 
 
 
 
 
11		
	
 Chapter 1: Introduction 
Atherosclerosis and atherosclerosis-associated conditions are major causes of 
morbidity and mortality among older adults in developed countries (Haerer, Delbaere, 
Bartlett, Lord, & Rowland, 2012).  Elevated blood cholesterol is a primary risk factor for 
atherosclerotic cardiovascular disease and contributes to one in three American deaths via 
heart attack or stroke (Gu, Paulose-Ram, Burt, & Kit, 2015).  More than 70% of adults 
are treated for high cholesterol with lipid-lowering prescriptions, which affect different 
components of one’s lipid profile (Gu et al., 2015).  Lipid-lowering agents include HMB-
CoA reductase inhibitors (statins), fibrates, bile acid sequestrants, or a combination of 
multiple medications for an increased effect on numerous lipid-profile targets.  By 2012, 
nearly 93% percent of adults using cholesterol-lowering medication used a statin, making 
statins one of the most commonly used classes of drugs in the United States (Gu et al., 
2015; Scott, Blizzard, Fell, & Jones, 2009). Statins inhibit endogenous cholesterol 
production at an early stage in the mevalonate pathway by inhibiting the enzyme HMG-
CoA reductase in the liver (Golomb & Evans, 2008).  Decreasing synthesis of cholesterol 
primarily through this pathway decreases downstream LDL synthesis and increases LDL 
receptor sensitivity, thereby minimizing atherosclerotic development by increasing 
clearance of LDLs from the blood (Stancu & Sima, 2001).  Although many people treated 
with statins experience little or no adverse effects, there is a need for awareness of risks 
and benefits of statin therapy (Golomb & Evans, 2008).  The best recognized and most 
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commonly reported adverse effects of statins include muscle pain, fatigue, 
weakness, and rhabdomyolysis (Stancu & Sima, 2001).  It is important to consider these 
risks when prescribing statins to older adults with a history of falls.  
  Older adults have increased fall risk because of age-related muscle decline, 
impaired balance, comorbidities, medication use, and increased frailty.  Given that statin 
usage and sarcopenia are both common with increased age, the association between statin 
use and muscle function in older adults requires clarification (Scott et al., 2009).  Because 
30-60% of older adults fall each year, and these falls result in injury, hospitalization or 
death, these falls must be further analyzed for preventive purposes (Rubenstein, 2006).  
Better prevention of falls in this population may be facilitated by broader identification of 
risk factors, and it has been postulated that statins may exacerbate age-related muscle 
decline, potentially increasing fall risk, but data are conflicted (Haerer et al., 2012).  
Although statins have been traditionally known to have a favorable safety profile and 
adverse effects are rare, the uncommon effects can translate into a significant public 
health impact (Golomb & Evans, 2008).   
Exercise has shown to enhance lipid profiles without the use of statins and may 
have an important role in negating the effects of statins on fall risk and sarcopenia in 
older adults (Trejo-Gutierrez & Fletcher, 2007).  
Research Hypothesis 
There will be a significant prediction in the number of previous admissions for falls by a 
diagnosis of dementia, use of statins, and self-reported balance.  
There will be a significant prediction in the number of subsequent admissions for fall 
injuries by a diagnosis of dementia, use of statins, and self-reported poor balance.  
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Purpose 
The purpose of this research is to examine the relationship between statin usage and 
previous fall admissions among older adults in a Level 1 trauma center.  
Null Hypothesis 
There will be no significant prediction of the number of the number of previous 
admissions for falls by a diagnosis of dementia, use of statins, and self-reported poor 
balance.  
There will be no significant prediction in the number of subsequent admissions for fall 
injuries by a diagnosis of dementia, use of statins, and self-reported poor balance. 
Delimitations 
People aged >65 from the Level 1 trauma center 
Limitations 
 
Study is not a randomized control trial 
All subjects are from a Level 1 trauma center 
No information of statin dosages for each patient 
Subject honesty when reporting self-reported balance 
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Chapter 2: Review of the Literature 
Fall Occurrence, Risk Factors, and Consequences 
 
According to the American Geriatrics Society, falls are quickly becoming the 
most frequent and serious problem facing the elderly as thirty percent of adults over the 
age of 65 and fifty percent of adults over the age of 80 fall annually while completing 
their activities of daily living in the community (Arnold, Sran, & Harrison, 2008; 
Dionyssiotis, 2012).  A fall has been defined as, “an event which results in a person 
coming to rest inadvertently on the ground or other lower level, not as a consequence of 
the following: sustaining a violent blow, loss of consciousness, sudden onset of paralysis, 
or an epileptic seizure” (Dionyssiotis, 2012, p. 805).  
The combination of high incidence of falling in older adults coupled with a higher 
susceptibility to injury of a fall are of great concern to this aging population and their 
families (Arnold et al., 2008).  Falls have a proven association with reduced functionality, 
morbidity, premature nursing home admissions, and mortality (Dionyssiotis, 2012).  As a 
result of these occurrences, there has been a steady increase in Emergency Department 
visits increasing direct and indirect costs of medical treatments to affected individuals, 
families, and medical providers.  More specifically, Stevens, Corso, Finkelstein, & Miller 
(2006) reported direct medical costs totaled $0.2 billion for fatal and $19 billion for non-
fatal fall related injuries among people aged 65 or older, underscoring the need for 
identification of risk factors and effective interventions (Stevens, Corso, Finkelstein, & 
Miller, 2006).  
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Older adults are inevitably more prone to falling due to physiological changes 
with age, such as osteoporosis, postural instability, gait disturbances, diminished muscle 
strength, poor vision and cognitive impairment, as well as the intake of multiple 
medications (Bunn, Dickinson, Barnett-Page, Mcinnes, & Horton, 2008).  The interaction 
of multiple and diverse risk factors and situations may be corrected, and their interaction 
is modified by age, disease, and the presence of various hazards in the environment 
(Dionyssiotis, 2012).  
The literature has structured older adult fall-risks into two broad categories: 
extrinsic and intrinsic factors. Extrinsic factors include environmental conditions such as 
poor lighting, slippery floors, and uneven surfaces (Dionyssiotis, 2012).  The magnitude 
of the influence of these environmental factors alone is uncertain, but they frequently 
interact with a person’s wide range of intrinsic factors.  Intrinsic factors include one’s 
history of falls, age, gender, solitary lifestyle, race, medical conditions, impaired mobility 
and gait, deconditioning/immobility, fear of falling, nutritional deficiencies, cognitive 
disorders, attenuated vision, and intake of various medications (Dionyssiotis, 2012).  One 
particular intrinsic factor warranting increased attention is the intake of various 
medications, as emerging studies are continually identifying this as a primary predictor of 
a future fall.  Until recently, most attention in the literature has focused on the effects of 
psychotropic, antiarrhythmic drugs, digoxins, diuretics, and sedatives as the predominant 
culprits for falls and fall-related injuries.  However, more recent studies are postulating 
that statins, a class of cholesterol-lowering medications, may exacerbate age-related 
muscle decline and may be a novel predictor for fall risk in the elderly (Dionyssiotis, 
2012; Haerer et al., 2012). 
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Statin Overview 
 
 Between 2003-2004, one in five adults reported using a cholesterol-lowering 
medication in the past 30 days to improve lipid profiles.  By 2011-2012, that number had 
increased to one in four adults (Gu et al., 2015).  Different types of cholesterol-lowering 
medications include: HMG-CoA reductase inhibitors (statins), bile acid sequestrants, 
niacins, fibrates, or PCSK6 injectable medications.  Statins are currently the most 
effective and most commonly prescribed lipid-lowering drug on the market.  They have 
revolutionized primary and secondary prevention of coronary atherosclerotic disease and 
hypercholesterolemia by strategically targeting specific components of one’s lipid profile 
(Abd & Jacobson, 2011; Wierzbicki, Poston, & Ferro, 2003). The CDC reported in 2011-
2012, 83% of adults reported using a statin alone, 10% reported combining a statin and a 
nonstatin, and only 7% reported the intake of a nonstatin alone to lower cholesterol 
levels.  
 Statins are typically classified by their chemical structure, which largely 
determines their mechanism of action and length of duration in the body.  The most 
commonly known statins include Atorvastatin (brand: Lipitor), Fluvastatin (Lescol, 
Lescol XL), Lovastatin (Mevacor, Altoprev for long-acting), Pravastatin (Pravachol), 
Simvastatin (Zocor), Rosuvastatin (Crestor), and Pitavastatin (Livalo) (Stancu & Sima, 
2001).  Cervistatin (Baycol, Lipobay) was previously on the pharmaceutical market from 
Bayer A.G., but was removed in 2001 after thirty-one patients died by acute renal failure 
caused by rhabdomyolysis in the United States (Stancu & Sima, 2001) and an additional 
twenty-one deaths worldwide (Furberg & Pitt, 2001).  Additionally, there were 385 
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nonfatal cases reported among the estimated 700,000 users in the United States, most of 
which required hospitalization (Furberg & Pitt, 2001).  
 Statins target hepatocytes and competitively inhibit HMG-CoA reductase, a key 
enzyme in the cholesterol-forming physiological pathway converting HMG-CoA into 
mevalonate (Stancu & Sima, 2001).  Primary targets of the drug include minimized low-
density lipoprotein cholesterol (LDL-C), decreased triglyceride levels, and/or increased 
high-density lipoprotein cholesterol levels (HDL-C) (Wierzbicki et al., 2003) which 
contribute to the downstream formation of cholesterol and other physiological 
byproducts.  
Cholesterol Synthesis 
 The synthesis of cholesterol is vital for the maintenance and structural integrity of 
various organ systems, cellular membranes, and is a precursor to produce other 
downstream products such as bile acids, steroid hormones, and vitamin D.  
 Cholesterol synthesis is often simplified into a series of three primary steps: the 
formation of mevalonate, the formation of isopentyl pyrophosphate, and the formation of 
cholesterol.  Synthesis begins with the oxidation of fatty acids or pyruvate into acetyl-
CoA and is then transported into the cytoplasm.  It is further metabolized in the 
cytoplasm, endoplasmic reticulum and the peroxisomes of the cell.  Two Acetyl-CoA 
molecules are acted on by Thiolase, an intracellular enzyme, in order to form Acetoacetyl 
CoA.  HMG-CoA synthase acts on Acetoacetyl-CoA to form B-hydroxyl-B-methyl-
glutaryl.  B-hydroxyl-B-methyl-glutaryl is catalyzed by HMG-CoA reductase to form the 
6-carbon Mevalonate compound.  We will revisit HMG-CoA reductase in further detail 
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in upcoming sections, as it is a common target for various cholesterol-lowering 
medications. 
 The next phase of the cholesterol synthesis pathway involves the conversion of 
the 6-carbon Mevalonate compound into a 5-carbon Isopentyl pyrophosphate compound.  
Mevalonate undergoes a series of three kinase reactions, adding a phosphate to the 
subsequent compound from an ATP molecule.  The final reaction after three kinase 
reactions is a decarboxylase reaction involving the removal of a carbon dioxide molecule. 
The final removal of the carbon dioxide forms the 5-carbon Isopentyl pyrophosphate 
molecule, which is later synthesized into a 27-carbon downstream cholesterol.  
 Isopentyl pyrophosphate undergoes a series of reactions combining carbon 
molecules to eventually form the 27-carbon cholesterol molecule.  Isopentyl 
pyrophosphate isomerase acts upon isopentyl pyrophosphate to form a 5-carbon Dimethyl 
pyrophosphate.  This 5-carbon molecule combines with an additional 5-carbon Isopentyl 
pyrophosphate to form the 10-carbon Geranyl pyrophosphate molecule.  Geranyl 
pyrophosphate combines with another Isopentyl pyrophosphate molecule to form a 15-
carbon Farnesyl pyrophosphate.  Farnesyl pyrophosphate can continue moving 
downstream in the cholesterol synthesis pathway, or has the potential for conversion into 
dolicohols or ubiquinone (CoQ10) for other intracellular functions (Wierzbicki et al., 
2003).  Two 15-carbon Farnesyl pyrophosphates continue through the cholesterol 
synthesis pathway in the endoplasmic reticulum to form a 30-carbon Squalene molecule.  
The enzyme Squalene synthase helps in the formation of the 30-carbon Squalene 
molecule.  Similar to HMG-CoA reductase, Squalene synthase is also a common target 
for cholesterol-lowering medications.  
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 Squalene is further metabolized in the endoplasmic reticulum or in nearby 
peroxisomes to form the 30-carbon Lanosterol molecule.  Lanosterol is then transformed 
through a series of nineteen additional reactions to form the final 27-carbon cholesterol 
molecule for a variety of future uses.  
 Figure 1 adapted from Wierzbicki et al. (2003) describes the 
compartmentalization and simplified biochemistry of cholesterol synthesis.  Common 
drug targets are shown in bold italics.  
 
 
 
Figure 1:  Compartmentation and Simplified Biochemistry of Cholesterol Synthesis.  
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The Role of Statins in Cholesterol Synthesis 
 The beneficial effects of HMG-CoA reductase inhibitors (statins) are attributed to 
their ability to reduce endogenous cholesterol production in the liver by competitively 
inhibiting the primary enzyme involved, HMG-CoA reductase (Stancu & Sima, 2001).  
Inhibiting this enzyme at an early stage in the mevalonate pathway produces pleiotropic 
effects, as cholesterol is not the only product in this pathway.  These effects, while often 
beneficial in lowering LDL-C levels, together may contribute to adverse effects to 
unregulated downstream targets.  For instance, Golomb and Evans (2008) highlight the 
need for cholesterol in the production of sex steroids, corticosteroids, bile acids, and 
vitamin D, which are indirectly affected by statin therapy (Golomb & Evans, 2008).  
Furthermore, cholesterol intermediates formed in the mevalonate pathway are also 
affected, as ubiquinone (CoQ10), heme-A, and isoprenylated protein production are 
hindered.  These molecules have pivotal roles in cellular biology and human physiology, 
and may be of potential relevance in the conversation about statins and their adverse 
effects, specifically muscle weakness and myopathy in the elderly population (Stancu & 
Sima, 2001).  
 Although multiple clinical trials have documented the relative safety and efficacy 
of statin medications in reducing fatal and non-fatal coronary heart disease, strokes, and 
overall mortality, there is emerging evidence that targeting the formation of certain lipids 
or cholesterols may negatively affect other physiological pathways, potentially leading to 
increased risk of various detrimental effects to one’s health.  Wierzbiki et al. (2003) note 
the principal side effects of statins are gastrointestinal disturbances, abnormal liver 
transaminases, and myalgia-myositis (Scott et al., 2009; Wierzbicki et al., 2003).  Of the 
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known statin-induced toxicities, muscle adverse effects are the most reported problem 
both in the literature and by patients (Golomb & Evans, 2008). 
 Although statin-induced myopathy is the most recognized adverse effect of the 
drug, reported measures have been inconsistent and perhaps underreported in 
epidemiological studies and in randomized control trials.  This inconsistency may be due 
to the absence of a consensus in the definition of statin-induced muscle events, hindering 
the estimation of their true incidence (Abd & Jacobson, 2011).  Statin-induced myopathy 
is the generalized term for four separate muscle adverse effects: myopathy, myalgia, 
myositis, and rhabdomyolysis.  These terms and their objective parameters have been 
defined inconsistently between the American College of Cardiology (ACC), American 
Heart Association (AHA), National Heart, Lung, and Blood Institute (NHLBI), and the 
National Lipid Association (NLA), making reporting of these adverse events 
unstandardized and potentially inaccurate.  Table 1 adapted from Abd & Jacobson (2011) 
demonstrates the inconsistencies in definitions between these four terms (Abd & 
Jacobson, 2011).  A more accurate and widely accepted definition of these conditions and 
corresponding chemical markers is warranted in order to best identify and treat this 
clinical problem.  Doing so may provide further transparency and analysis between 
randomized control trials regarding statin-induced myopathy and the predictors for 
potential falls.  
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Table 1.  Proposed Definitions for Statin-Related Myopathy. 
 
 
 
 
Proposed Mechanisms of Statin-Induced Myopathy 
 Recent clinical reports have confirmed suspicions that statins frequently produce 
muscle symptoms.  For instance, Parker & Thompson (2012) analyzed 7924 patients 
treated with high dose statins and found that 11% developed muscle symptoms, 4% had 
symptoms severe enough to interfere with daily activities, and 0.4% were actually 
confined to bed with their symptoms (Parker & Thompson, 2012).  In another report by 
Abd & Jacobson, researchers found that 10-15% of statin users also developed these 
muscle effects ranging from mild myalgia to more severe muscle symptoms involving 
elevated creatine kinase levels (Abd & Jacobson, 2011). 
 The exact mechanisms of statin-induced myopathy have not yet been confirmed, 
but studies suggest the multi-branched effects of statins and their numerous targets in the 
cholesterol-forming pathway may be of significant impact.  Abd et al. (2011) summarize 
some of the leading theories including isoprenoid depletion, inhibition of ubiquinone 
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synthesis (CoQ10), decreased or altered sarcolemmal membrane cholesterol, disturbed 
calcium metabolism, or autoimmune phenomena.  
 By inhibiting the formation of mevalonate through competitive binding of statins 
to the HMG-CoA reductase enzyme, mevalonate production is decreased and 
downstream lipids are also minimized during production.  Isoprenoids are one type of 
specific lipid byproducts produced through the HMG-CoA reductase pathway in 
cholesterol synthesis and serve as attachments for a variety of intracellular signaling 
molecules (Liao, 2002).  The two most important subclasses of isoprenoids formed 
through this pathway are farnesyl pyrophosphate (F-PP) and geranylgeranyl 
pyrophosphate (GG-PP) which are attached to proteins by the process of protein 
prenylation, a post-translational process at the terminal end of mRNA (Abd & Jacobson, 
2011).  Statins reduce protein prenylation, promoting downstream alternative 
modifications to small GTPases (Rho, Ras, Rac) and lamin proteins.  This modification 
may lead to downstream vacuolation of myofibers, degeneration and swelling of 
organelles, increased susceptibility to mechanical stress, and eventually cell death (Abd 
& Jacobson, 2011).  
 More recent research has noted a relationship between statin therapy and serum 
Ubiquinone (CoQ10) levels.  CoQ10 is an key component of oxidative phosphorylation 
and ATP production in the mitochondria (Abd & Jacobson, 2011).  As statins inhibit 
mevalonate production, the synthesis of the precursor of CoQ10 is also minimized.  
Inhibiting the synthesis of CoQ10 has been suggested to compromise the function of 
mitochondrial respiration and may impair energy production and ultimately induce 
myopathy, but data are conflicted. 
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 Reduced cholesterol levels from statin therapy may also cause alterations in 
myocyte membrane cholesterol by adversely modifying their physical properties, such as 
the integrity and fluidity of the conjoined phospholipids, and destabilizing membranes 
(Abd & Jacobson, 2011).  
 Calcium is a critical component in regulating skeletal muscle function.  The 
regulation and uptake of calcium is regulated through L-type calcium channels on 
intracellular membranes and RYR receptors found on the sarcoplasmic reticulum (Abd & 
Jacobson, 2011).  In studies looking into muscle biopsies of patients with myopathy, 
researchers found increased expression of RYR receptors and structural changes in the T-
tubule structure of the sarcoplasmic reticulum. It has been postulated therefore that statin 
therapy may alter calcium handling such that calcium leaking from the mitochondria may 
impair SR calcium cycling and increases resting cytosolic calcium (Parker & Thompson, 
2012).  
 More research is warranted on the effect of statins on patients with certain 
autoimmune disorders such as polymyositis, lupus, and myasthenia gravis.  The 
mechanism regarding this statin-induced aggravation has yet to be confirmed but may 
include the upregulation of MHC-1 expression and antigen presentation in muscle fibers 
(Abd & Jacobson, 2011).  As a result, statins have been reported to cause severe immune-
mediated necrotizing myopathy to this population.  
The mechanism by which statins produce myopathic symptoms is unclear, but 
numerous hypotheses have been proposed on the mechanisms of statin-induced 
myopathy.  Decreased sacroplasmic reticular cholesterol, reduced production of CoQ10 
required for mitochondrial electron transport, decreased production of prenylated 
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proteins, changes in fat metabolism, increased uptake of cholesterol, failure to replace 
damaged muscle protein via the ubiquitin pathway, disruption of calcium metabolism in 
the skeletal muscle and inhibition of various protein synthesis have all been suggested as 
possible mediators (Krishnan & Thompson, 2010).  
Statins and Fall-Risk  
As emerging studies continue to identify the molecular mechanisms for statin-
induced myopathy on a molecular scale, it is also important to take note of the 
consequences of these molecular changes to the general population on a larger scale.  
Evidence for an association between statins and increased fall-risk is inconsistent 
throughout the literature.  A systematic review by Krishnan and Thompson (2010) 
document that there are few studies examining the effect of statins on muscle strength 
and capacity.  In addition, of the available clinical trials, muscle strength was often 
measured by crude or poorly described techniques (Krishnan & Thompson, 2010).  
 When examining the literature to determine if a relationship exists between statin-
therapy and fall-risk, the data are conflicted.  In current clinical practice, physicians often 
monitor patients taking statins by monitoring their creatine kinase levels, a commonly 
referenced chemical marker to determine the scope of one’s muscle damage from 
metabolizing a statin medication.  If creatine kinase levels are within normal limits, 
patients are encouraged to continue with statin therapy (Mohaupt et al., 2009).  Phillips et 
al. (2002) was the first to examine the effects of statin-induced myopathy in patients with 
normal creatine kinase levels. Philips et al., however, highlight that some patients who 
develop muscle symptoms while receiving statin therapy have demonstrated weakness in 
hip abductors and hip flexors without rising serum levels of creatine kinase, further 
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highlighting the importance of a need for an improved myopathy definition and testing 
parameters to analyze statin-induced adverse effects (Phillips et al., 2002).  
The relationship between statin-induced myopathy and skeletal muscle strength is 
also conflicted in the literature.  Scott et al. (2009) employed a prospective cohort design 
to examine the effects of statin therapy on muscle function and muscle mass for people 
aged 50-79 years (Scott et al., 2009).  At a 2.6 year follow up, statin users had a 
significantly lower mean leg strength than non-statin users at follow up, and muscle 
strength and quality decreased significantly in those who reported statin use at baseline 
and follow up when compared to all other patients (Parker & Thompson, 2012; Scott et 
al., 2009).  Dobkin (2005) found similar results in subjects three to twelve months after 
taking a statin.  Subjects experienced difficulty walking and rising from a chair after 
starting statin therapy (Dobkin, 2005).  
Alternatively, emerging studies reveal conflicting evidence between fall-risk and 
statin therapy and suggest there is no adverse effect of the medication.  Contrary to 
Dobkin (2005), Agnostini et al. (2007) found statin use to be associated with slightly 
improved performance in timed standing tests among community-dwelling males 
(Agostini et al., 2007).  These subjects had been taking the medications for at least one 
year before enrollment, suggesting they may have tolerated the medication beforehand.  
Similarly, Ashfield et al. (2010) found no association of statin use with handgrip with a 
dynamometer, a predictor of increased falls, fractures, and morbidity in elderly 
populations (Ashfield et al., 2010; Krishnan & Thompson, 2010).  
Variations in the literature may be attributed to a lack of a consensuses in a 
clinical definition and chemical markers for statin-induced myopathic symptoms, 
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inconsistencies in functional tests used among trials, sample sizes, sex, and comorbidities 
of subject populations (Haerer et al., 2012).  Differences seen in clinical trials may be due 
to the fact that healthy participants were used as subject for most clinical trials and are 
less likely to report occasional mild side effects of the medications (Abd & Jacobson, 
2011).  It is also important to note that clinical trials often exclude subjects with a high 
risk of developing statin myopathy (such as those with previous myopathy, or those 
taking medications that may interact with statins) in clinical trials (Abd & Jacobson, 
2011).  It is important to highlight that most previous studies have included a limited 
range of muscle strength tests, and few have examined the precise relationship between 
statin use and prospectively measured falls (Haerer et al., 2012).  
The possible adverse effects of statins coupled with age-related declines supports 
the need for further investigation on the relationship between fall-risk and statin use, 
especially among older adults.  The aims of this study therefore, were to investigate the 
relationship between statin usage and previous fall-related emergency department 
admissions among older adults.  
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Chapter 3: Methodology 
This chapter will provide discussion regarding the research design and 
experimental procedures taken to answer the research question of the study.  Subject 
population, instrumentation, assessment measures, experimental interventions, and 
ethical concerns will be presented and further discussed in the upcoming sections. 
Data Acquisition and Management 
 All data concerning patient demographics, diagnoses, associated injuries, self-
report problems, and medications were exported from the institution’s trauma registry.  
We examined all patients who were admitted to the emergency room with a mechanism 
of injury of a fall and were discharged from the emergency room with no codable 
injuries.  A database was composed of patient medical numbers, age, sex, type of injury, 
discharge diagnosis, home medications, associated medical conditions, number of falls 
known, number of return emergency room visits, self-reporting of poor balance, 
lightheadedness, visual impairment, any cognitive struggles, fall risk score documented 
by nursing, known reason for fall, and any other medical conditions documented from the 
patient’s history. 
Subjects  
We retrospectively analyzed the patient registry of an ACS-verified Level 1 
Trauma Center.  All patients aged > 65 years who were admitted for a fall-related injury 
in 2015 were included (n=615).  Demographic data (age, sex) diagnoses (e.g., dementia, 
hypertension, etc.) associated injuries (e.g., head trauma, laceration, etc.), self-report 
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problems (e.g., poor balance), and medications exported.  Many of these patients 
had been previously admitted for falls and many were later readmitted for falls.  We 
recorded the total number of previous admissions and return admissions.  The medication 
of interest was statins; we compared the number of previous falls of patients using statins 
to that of patients not using statins.  We then compared the number of subsequent falls 
between patients using and not using statins. 
Statistical analysis.  All statistical tests were conducted using SPSS version 22 
(IBM SPSS Statistics, IBM Corporation, Chicago, IL, USA).  Descriptive statistics 
(percentages, means, and standard deviations) of the sample population were calculated.  
Group means were compared with independent sample t-tests.  Differences in categorical 
data were measured with chi-square tests. Linear regression analyses tested the effects of 
statins, dementia, and self-reported balance measurements on 1) the number of previous 
admissions for falls, and 2) the number of subsequent admissions for falls.  Significance 
was set at p>0.05. Predictors that did not meet significance were removed from the 
model.  
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Chapter 4: Draft of Manuscript 
Title 
  Using the Medication Cabinet to Predict Fall Risk in Older Adults 
Abstract  
Background.  In the United States, 30-60% of older adults fall each year; 10-20% of 
these falls result in injury, hospitalization, or death.  Better prevention of falls in this 
population may be facilitated by broader identification of risk factors.  The use of statins 
has emerged as a potential risk factor, but the data are conflicted. Purpose.  To examine 
the relationship between statin use and falls among community-dwelling older adults. 
Methods.  The patient registry of a Level 1 trauma center was evaluated.  All patients 
aged > 50 years who were admitted for falls in 2015 were included (n=615).  Many of 
these patients had been previously admitted for falls and many were later readmitted for 
falls.  We analyzed predictors of both prior admission and readmission with linear 
regression.  Independent variables were self-reported balance problems, diagnosis of 
dementia, and the use of statins.  Results.  On average, patients admitted for falls were 
79.9 + 9.3 years old and 28% (n=173) were taking statins.  Our collection of predictors 
explained 14.2% of the variance in the number of prior admissions (p<0.001).  In this 
model, the use of statins significantly predicted the number of previous fall-related 
admissions (95% CI: 0.07–0.50, p=0.010).  This same model maintained significance 
when predicting admissions for future falls (p<0.001) and the use of statins continued to 
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predict a greater number of readmissions (95% CI: 0.04–0.36, p=0.015).  Conclusion.  
Statin medication therapy increases the risk for falls in patients over 65 years old.  This 
finding is significant since more than 25% of all Americans age > 40 years are taking 
cholesterol-lowering medication, and 93% of those medications are statins.  Exercise 
training should be considered as a prophylactic measure as it improves lipid profiles and 
may also improve balance, coordination, and mobility, may reduce fall-related injuries. 
Introduction 
Atherosclerosis and atherosclerosis-associated conditions are major causes of 
morbidity and mortality among older adults in developed countries (Haerer et al., 2012).  
Elevated blood cholesterol is a primary risk factor for atherosclerotic cardiovascular 
disease and contributes to one in three American deaths via heart attack or stroke (Gu et 
al., 2015).  More than 70% of adults are treated for high cholesterol with lipid-lowering 
prescriptions, which affect different components of one’s lipid profile (Gu et al., 2015).  
By 2012, nearly 93% percent of adults using cholesterol-lowering medication used a 
statin, making statins one of the most commonly used classes of drugs in the United 
States (Gu et al., 2015; Scott et al., 2009).  Although many people treated with statins 
experience little or no adverse effects, there is a need for awareness of risks and benefits 
of statin therapy (Golomb & Evans, 2008).  The best recognized and most commonly 
reported adverse effects of statins include muscle pain, fatigue, weakness, and 
rhabdomyolysis (Stancu & Sima, 2001).  Although statin-induced myopathy is the most 
recognized adverse effect of the drug, reported measures have been inconsistent and 
perhaps underreported in epidemiological studies and in randomized control trials.  This 
inconsistency may be due to the absence of a consensus in the definition of statin-induced 
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muscle events, hindering the estimation of their true incidence (Abd & Jacobson, 2011).  
It is important to consider these risks when prescribing statins to older adults with a 
history of falls.  Given that statin usage and sarcopenia are both common with increased 
age, the association between satin use and muscle function in older adults requires 
clarification (Scott et al., 2009).  Because 30- 60% of older adults fall each year, and 
these falls result in injury, hospitalization or death, these falls must be further analyzed 
for preventive purposes (Rubenstein, 2006).  Better prevention of falls in this population 
may be facilitated by broader identification of risk factors, and it has been postulated that 
statins may exacerbate age-related muscle decline, potentially increasing fall risk, but 
data are conflicted (Haerer et al., 2012). 
Methods 
Subjects.  We retrospectively analyzed the patient registry of an ACS-verified 
Level 1 Trauma Center.  All patients aged > 65 years who were admitted for a fall-related 
injury in 2015 were included (n=615).  Demographic data (age, sex) diagnoses (e.g., 
dementia, hypertension, etc.) associated injuries (e.g., head trauma, laceration, etc.), self-
report problems (e.g., poor balance), and medications exported.  Many of these patients 
had been previously admitted for falls and many were later readmitted for falls.  We 
recorded the total number of previous admissions and return admissions.  The medication 
of interest was statins; we compared the number of previous falls of patients using statins 
to that of patients not using statins.  We then compared the number of subsequent falls 
between patients using and not using statins. 
Statistical Analysis.  All statistical tests were conducted using SPSS version 22 
(IBM SPSS Statistics, IBM Corporation, Chicago, IL, USA).  Descriptive statistics 
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(percentages, means, and standard deviations) of the sample population were calculated.  
Group means were compared with independent sample t-tests.  Differences in categorical 
data were measured with chi-square tests.  Linear regression analyses tested the effects of 
statins, dementia, and self-reported balance measurements on 1) the number of previous 
admissions for falls, and 2) the number of subsequent admissions for falls.  Significance 
was set at p>0.05. Predictors that did not meet significance were removed from the 
model. 
Results 
On average, patients admitted for falls were 79.9 ± 9.3 years old and 28% (n=173) 
were taking statins.  There was no difference in age between patients taking statins and 
those not taking statins, but there is a small difference in sex (Table 2). 
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Table 2.  Demographic Data, Number of Falls, and Diagnoses 
 
 
Model 1.  Predictors of previous admissions for fall-related injuries: The stepwise 
regression model that best predicted number of previous admissions for falls included: a 
diagnosis of dementia, self-reported poor balance during a visit, and use of statins.  This 
collection of predictors explained 14.2% of the variance in the number of previous 
admissions (R2=0.142, standard error of the estimate=1.215, F=33.80, P<0.001).  With all 
other variables held constant, administering statin therapy to a patient predicted a 
significant increase in the number of previous admissions for fall-related injuries (95% 
CI: 0.07–0.50, p=0.010).  
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Table 3.  Linear Regression Analysis Predicting Number of Previous Admissions for 
Falls. 
 
 
Model 2.  Predictors of subsequent admissions for fall-related injuries: The 
stepwise regression model that best predicted the number of subsequent admission for fall 
injuries included: A diagnosis for dementia, self-reported poor balance during visit, and 
use of statins.  This collection of predictors explained 9.0% of the variance in the number 
of subsequent falls (R2=0.092, standard error of the estimate =0.902, F=20.726, P<0.001).  
The use of statins predicted a greater number of readmissions for fall-related injuries 
(95% CI: 0.04–0.36, p=0.015).  
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Table 4.  Linear Regression Analysis Predicting Number of Return Emergency Room 
Visits. 
 
 
Discussion 
More than 30% of people over 65 years of age fall each year and in half of these 
cases, falls are recurrent (Dionyssiotis, 2012).  The combination of high incidence of 
falling in older adults coupled with a higher susceptibility to injury of a fall are of great 
concern to this aging population and their families (Arnold et al., 2008).  Falls have a 
proven association with reduced functionality, morbidity, premature nursing home 
admissions, and mortality (Dionyssiotis, 2012).  As a result of these occurrences, there 
has been a steady increase in Emergency Department visits which increases direct and 
indirect costs of medical treatments to individual fallers, families, and medical providers, 
underscoring the need for identification of broader risk factors and effective interventions 
(Stevens et al., 2006).  Older adults are inevitably more prone to falling due to 
physiological changes with age, such as osteoporosis, postural instability, gait 
disturbances, diminished muscle strength, poor vision and cognitive impairment, as well 
as the intake of multiple medications (Bunn et al., 2008).  
Medication intake has warranted increased attention, as emerging studies are 
continually identifying this as a significant predictor for a future fall.  Most attention has 
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focused on the effects of psychotropic, antiarrhythmic, digoxins, diuretics, and sedatives 
as the predominant culprits for falls and fall-related injuries.  However, more recent 
studies are postulating that statins, a class of cholesterol-lowering medications, may 
exacerbate age-related muscle decline and may be a novel predictor for fall risk in the 
elderly (Dionyssiotis, 2012; Haerer et al., 2012). 
More than 25% of Americans age ≥ 40 years are taking cholesterol-lowering 
medication; 93% of those medications are statins (Gu et al., 2015).  Although multiple 
clinical trials have documented the relative safety and efficacy of statin medications in 
reducing fatal and non-fatal coronary heart disease, strokes, and overall mortality, there is 
emerging evidence that targeting the formation of certain lipids or cholesterols with 
statins may be pleiotropic, potentially leading to increased risk of detrimental effects to 
one’s health.  Of the known statin-induced toxicities, muscle adverse effects are the most 
reported problem both in the literature and by patients (Golomb & Evans, 2008) and may 
be a contributor to increased fall risk with statin therapy.  
Our data support the finding that statin therapy increases the risk of falls in older 
adults, although evidence is conflicted.  Patients are prescribed statins as a means to 
combat unfavorable lipid profiles and prevent atherosclerotic cardiovascular disease.  
Patients and physicians should be made aware that while there are benefits of statin 
therapy, there are adverse effects to these medications that may cause an increase for fall-
risk in this population.  It may also be appropriate to emphasize alternative treatments to 
statin therapy such as lifestyle modifications, diet, and implementation of an exercise 
regimen, as a fall-related injury may accelerate the path towards a life-threatening fall-
related injury or death.  Identifying patients who present with our collection of predictors 
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and suggesting an improvement in their dietary habits, medication use, or referral to 
balance may be appropriate to minimize risk for a future fall.  Exercise may function as a 
prophylactic measure, enhancing lipid profiles and decreasing the need for statins while 
also improving balance, coordination, and mobility, reducing the risk of fall-related 
injuries (Arnold et al., 2008; Trejo-Gutierrez & Fletcher, 2007). 
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APPENDIX A. SPSS LINEAR REGRESSION OUTPUTS FOR MODEL 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Independent variables: Diagnosis of dementia, self-reported poor balance during visit, 
and use of statins. 
 
Dependent variable: The number of previous admissions for falls. 
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APPENDIX B. SPSS LINEAR REGRESSION OUTPUTS FOR MODEL 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Independent variables: Diagnosis of dementia, self-reported poor balance during visit, 
and use of statins. 
 
Dependent variable: The number of subsequent admissions for fall injuries. 
